AuntMinnie

JULY 12, 2024

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. A key mistake you can make early is not identifying your stakeholders, understanding their expertise, and including them. "If The bottom line?

Nuclear Medicine 105

Nuclear Medicine Radiation Oncology Radiopharmaceuticals Radiation 105

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,

Diagnostic 97

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 97

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

Imaging Technology

OCTOBER 5, 2023

Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering. Blue Earth Diagnostics received U.S.

Diagnose 52

Diagnose Diagnostic Disease Radiation 52

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 PET imaging currently under review by the U.S.

Diagnostic 98

Diagnostic Radiopharmaceuticals Imaging Radiation 98